Adaptive Biotechnologies Corp Stock Operating Margin
| ADPT Stock | USD 2.44 0.31 11.27% |
Adaptive Biotechnologies Corp fundamentals help investors to digest information that contributes to Adaptive Biotechnologies' financial success or failures. It also enables traders to predict the movement of Adaptive Stock. The fundamental analysis module provides a way to measure Adaptive Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptive Biotechnologies stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (1.18) | (1.24) |
Adaptive | Operating Margin |
Adaptive Biotechnologies Corp Company Operating Margin Analysis
Adaptive Biotechnologies' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Adaptive Biotechnologies Operating Margin | (1.00) % |
Most of Adaptive Biotechnologies' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adaptive Biotechnologies Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adaptive Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Adaptive Biotechnologies is extremely important. It helps to project a fair market value of Adaptive Stock properly, considering its historical fundamentals such as Operating Margin. Since Adaptive Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adaptive Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adaptive Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Adaptive Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Adaptive Biotechnologies Corp has an Operating Margin of -0.9968%. This is 97.16% lower than that of the Life Sciences Tools & Services sector and 99.11% lower than that of the Health Care industry. The operating margin for all United States stocks is 81.91% lower than that of the firm.
Adaptive Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptive Biotechnologies' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics of similar companies.Adaptive Biotechnologies is currently under evaluation in operating margin category among related companies.
Adaptive Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptive Biotechnologies from analyzing Adaptive Biotechnologies' financial statements. These drivers represent accounts that assess Adaptive Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptive Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.1B | 7.8B | 3.9B | 1.1B | 707.5M | 672.1M | |
| Enterprise Value | 2.0B | 7.7B | 3.9B | 1.1B | 871.8M | 828.3M |
Adaptive Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 281.91 M | ||||
| Shares Outstanding | 145.09 M | ||||
| Shares Owned By Insiders | 2.80 % | ||||
| Shares Owned By Institutions | 97.59 % | ||||
| Number Of Shares Shorted | 9.1 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 2.56 X | ||||
| Revenue | 170.28 M | ||||
| Gross Profit | (13.66 M) | ||||
| EBITDA | (179.38 M) | ||||
| Net Income | (225.25 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 229.43 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (156.32 M) | ||||
| Short Ratio | 5.80 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Target Price | 6.4 | ||||
| Number Of Employees | 709 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 399 M | ||||
| Total Asset | 661.13 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 322.17 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
| Net Asset | 661.13 M |
About Adaptive Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptive Biotechnologies Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
| 0.78 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.75 | ME | 23Andme Holding | PairCorr |
Moving against Adaptive Stock
| 0.86 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.73 | DOMH | Dominari Holdings | PairCorr |
| 0.64 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.61 | VCEL | Vericel Corp Ord Financial Report 8th of May 2024 | PairCorr |
| 0.57 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Adaptive Biotechnologies Piotroski F Score and Adaptive Biotechnologies Altman Z Score analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.